April 02, 2015
Accenture Life Sciences Expands Its Cloud Capabilities for R&D with Advanced Clinical Trial Automation Services
NEW YORK; April, 2, 2015 – Accenture has expanded its Accelerated R&D Services by selecting Medidata Solutions’ cloud-based electronic data capture and management system – Medidata Rave® – to complement its cloud-based solution. Accenture’s Accelerated R&D Services help clients streamline clinical trial set-up time and improve data efficiency, productivity, and transparency. Medidata’s technology platform provides a set of solutions, benchmarking data and industry analytics to improve operational efficiencies, resource savings and decision-making processes.
As part of Accenture Accelerated R&D services, Accenture is also enhancing its Life Sciences Cloud for R&D solution by integrating it with the Medidata Clinical Cloud®—a vertical software-as-a-service (SaaS) platform designed to transform the clinical research process for life sciences companies and the patients who depend on them by increasing speed to market, lowering risk, and improving therapeutic value. The integrated offering will enable life sciences companies to configure their clinical data warehouses based upon trial design in Rave. Together, Accenture and Medidata are creating submission-compliant deliverables to help clients address regulatory needs early.
“Accenture has taken another significant step by expanding Accenture Accelerated R&D Services with the addition of Medidata Rave® to help reduce our clients’ clinical setup time by up to 50 percent, while improving data quality and analytic reporting efficiency,” said Kevin Julian, managing director of Accelerated R&D Services, Accenture Life Sciences. “We have created a comprehensive, technology-enabled business service to accelerate and improve the drug development cycle for our clients.”
Accenture and Medidata have collaborated closely on a range of projects to deliver technology solutions and services to global pharmaceutical companies since 2002.
“We are pleased that Accenture has selected Medidata’s technology to power this expansion of its cloud capabilities for life sciences R&D and proud to be working with a company that shares our commitment to accelerating return on investment for clients,” said Steve Hirschfeld, Medidata’s chief commercial officer. “Accenture’s ability to rapidly complete the Rave accreditation process is a testament to our joint efforts to provide advanced clinical trial automation services that bring real value to customers.”
Julian added, “Our work with Medidata and recent Rave accreditation strengthens our position to provide standards-driven, collaborative, cloud-based solutions and services to help our clients maximize the value and effectiveness of their product portfolios.”
Accenture Accelerated R&D Services combines our capabilities across strategy, technology, analytics and operations, to simplify and accelerate the journey from early clinical trials to regulatory approval and throughout the product lifecycle. Our services leverage deep industry experience and customer insights to improve business outcomes and help customers bring new medicines to patients faster.
Accenture is a global management consulting, technology services and outsourcing company, with more than 323,000 people serving clients in more than 120 countries. Combining unparalleled experience, comprehensive capabilities across all industries and business functions, and extensive research on the world’s most successful companies, Accenture collaborates with clients to help them become high-performance businesses and governments. The company generated net revenues of US$30.0 billion for the fiscal year ended Aug. 31, 2014. Its home page is www.accenture.com.
About Medidata Solutions
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud® brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.
# # #
+ 1 312 693 5992